Publication

TM Publications: 1997-2007: V BARAK

  1. Merimsky O, Hareuveni M, Barak V, Sperber F, Keydar Y, Chaitchik S: The contribution of Tumor Markers to diagnosis of early breast cancer by screening mammography. Oncology Reports 1997; 4:17-21.
  2. Barak V, Nisman B, Roisman I, Hubert A, Farbstein H, Baider L, Kaplan A, HalperinT, Stephanos S, and Peretz T: TPS in assessing response to therapy and prognosis of Breast Cancer patients treated with interferons. J Tumor Marker Oncology 1997; 12(4):17-26.
  3. Levy Y, George J, Barak V, and Shoenfeld Y: Early detection of recurrent monometastases of breast cancer to endocrine tissues by following  CEA levels. Oncology Reports 1997; 4:623-624.
  4. Nisman B, Lafair J, Lyass O, Dranitzki-Elhalel M and Barak V: Serum Levels of CEA, SCC, TPS and CYFRA 21-1 in Hemodialysis Patients. J Tumor Marker Oncology 1998; 13(2):87-93.
  5. Nisman B, Lafair J, Heshing J, Lyass O, Peretz T, Barak V: Evaluation of TPS, Cyfra 21-1 and CEA in non-small cell lung cancer: does the combined use of cytokeratin markers give any additional information. Cancer 1998; 82:1850-1859.
  6. Van Dalen A, Barak V, Cremaschi A, Gion M, Molina R, Namer M, Stieber P,  Sturgeon C, Einarsson R: The prognostic significance of increasing marker levels in metastatic breast cancer patients with  clinically complete remission, partial remission or stable disease. Int J Biol Markers 1998; 13(1):10-15.
  7. Nisman B, Barak V, Heching N, Kramer M, Reinus C, LafairJ:  Cytokeratin markers in Malignant Pleural Mesothelioma. Cancer Det Prevent 1998; 22(5):416-422.
  8. Barak V, Nisman B, Polliack A: TNF family in hairy cell leukemia - correlation to disease activity and prognosis. Eur J Haematol 1999; 62:71-75.
  9. Nisman B, Amir G, Lafair J,Heshing J, Liass O, Peretz T, Barak V: Prognostic value of TPS, Cyfra 21-1 and CEA in different histologic types of non-small cell  lung cancer (NSCL). Anticancer  Research 1999; 19(5):3549-3552.
  10. Nisman B, Heching N and  Barak V: Serum tumor markers in resectable and non-resectable non-small cell lung cancer (NSCLC). J Tumor Marker Oncology 2000; 15(3), 11-23.
  11. Barak V,  Nisman B, Hubert A, Lyass O, Kaduri L, Peretz T: Prognostic efficacy of TPS in breast cancer. J Tumor Marker Oncology 2000; 15(3), 4-10.
  12. Einarsson R and Barak V: TPS: A Cytokeratin serum Tumor Marker for effective therapy control of cancer patients with  focus on breast cancer. J Clinical Ligand Assay 2000; 22(4), 348-352.
  13. Gavish Z, Pinthus J, Barak V, Ramon J, Nagler A, Eshhar Z, Pines M: Growth inhibition of prostate cancer xenografts by Halofuginone. The Prostate 2002; 51: 73-83.
  14. Nisman B, Barak V, Shapiro A, Golijanin D, Peretz T,  Pode D: Evaluation of Urine CYFRA 21-1 for the Detection of Primary and Recurrent Bladder Cancer. Cancer 2002;  94:2914-2922.
  15. Barak V, Nisman B, Hubert A, Lyass O, Peretz T: Cytokeratins - Clinical utility in breast cancer. Journal of clinical ligand assay 2002; 35(1): 40-42.
  16. Nisman B, Barak V, Hubert A, Kaduri L, Lyass O, Baras M, Peretz T: Prognostic factors for survival in metastatic breast cancer during first-line paclitaxel  chemotherapy. Anticancer Research 2003; 23:1939-1942. 
  17. Barak V, Goike H, Panaretakis K and Einarsson R : Clinical utility of cytokeratins as tumor markers- Review Clin Biochem 2004; 37(7): 529-540. 
  18. Molina R, Barak V, van Dalen A, Duffy M, Einarsson R, Gion M, Goike H, Lamerz R, Nap M, Soletormos G, Stieber P: Tumor markers in Breast Cancer - Recommendations. European Group of Tumor Markers (EGTM)  Tumor Biology 2005; 26: 281-293.
  19. Nisman B, Heshing N, Biran H, Barak V and  Peretz T: The prognostic significance of pretreatment circulating neuroendocrine markers chromogranin A and Pro-Gastrin releasing peptide in patients with  advanced NSCLC. Tumor Biology 2006; 27: 8-16. 
  20. Kadkol S, Lyn A, Barak V, Kalickman I, Leach L, Valyi-Nagy K, Majumdar D, Setty S, Maniotis A, Folberg R and Pe'er J: Osteopontin expression and serum levels in metastatic uveal melanoma:  a pilot study. IOVS 2006; 47(3): 802-806.
  21. Barak V, Frenkel S, Kalickman I, Maniotis A, Folberg R and Pe'er J: Serum markers to detect metastatic uveal melanoma.Anti-Cancer Research 2007; 27;1897-1900.
  22. Kadkol S, Lyn A, Barak V, Valyi-Nagy K, Majumdar D, Setty S, Maniotis A, Folberg R and Pe'er J: Modeling the behavior of uveal melanoma in the Liver. IOVS 2007; 48(7): 2967-2974.
  23. Barak V, Frenkel S, Valyi-Nagy K, Leach L, Apushkin MA, Lin A. Kalickman I, Baumann NA, Pe'er J, Maniotis A, Folberg R: Using the direct injection model of early uveal melanoma: hepatic metastases to identify TPS as a potentially useful serum biomarker. IOVS 2007; 48(10): 4399-4402.